A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.

NCT01227707 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: bevacizumab [Avastin]
DRUG: capecitabine [Xeloda]
RADIATION: Radiation therapy
PROCEDURE: Mesorectal excision
DRUG: bevacizumab [Avastin]
DRUG: 5-fluorouracil
DRUG: leucovorin

Sponsor

Hoffmann-La Roche